• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Generation Bio Co.

    3/24/23 4:27:53 PM ET
    $GBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GBIO alert in real time by email
    SC 13G 1 d453437dsc13g.htm SC 13G SC 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. _) *

     

     

    Generation Bio Co.

    (Name of Issuer)

    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)

    37148K100

    (CUSIP Number)

    March 24, 2023

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☒ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 37148K100

     

      1.    

      Names of Reporting Person

     

      ModernaTX, Inc.

      2.  

      Check the Appropriate Box if a Member of a Group (See Instructions)

     

      (a)  ☐        (b)  ☐

      3.  

      SEC Use Only

     

      4.  

      Citizenship or Place of Organization

     

      Delaware

    Number of

    Shares

     Beneficially 

    Owned by

    Each

    Reporting

    Person

    With

       5.    

      Sole Voting Power

     

      5,859,375

       6.  

      Shared Voting Power

     

      0

       7.  

      Sole Dispositive Power

     

      5,859,375

       8.  

      Shared Dispositive Power

     

      0

      9.    

      Aggregate Amount Beneficially Owned by Each Reporting Person

     

      5,859,375

    10.  

      Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)

     

      ☐

    11.  

      Percent of Class Represented by Amount in Row (9)

     

      8.9% (1)

    12.  

      Type of Reporting Person (See Instructions)

     

      CO

     

    (1)

    Percentage ownership is calculated based on 65,525,133 shares of Common Stock outstanding, consisting of the 5,859,375 shares of Common Stock issued to the Reporting Person and the 59,665,758 shares of Common Stock outstanding as of February 17, 2023 reported in the Issuer’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on February 23, 2023.


    Item 1.

     

      (a)

    Name of Issuer

    Generation Bio Co. (the “Issuer”)

     

      (b)

    Address of Issuer’s Principal Executive Offices

    301 Binney Street

    Cambridge, MA 02142-1071

     

    Item 2.

     

      (a)

    Name of Person Filing

    ModernaTX, Inc.

     

      (b)

    Address of Principal Business Office or, if none, Residence

    c/o Moderna, Inc.

    200 Technology Square

    Cambridge, MA 02139

     

      (c)

    Citizenship

    Delaware

     

      (d)

    Title of Class of Securities

    Common Stock, $0.0001 par value per share

     

      (e)

    CUSIP Number

    37148K100

     

    Item 3.

    If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a)

     

    ☐

      

    Broker or dealer registered under Section 15 of the Act;

    (b)   ☐    Bank as defined in Section 3(a)(6) of the Act;
    (c)   ☐    Insurance company as defined in Section 3(a)(19) of the Act;
    (d)   ☐    Investment company registered under Section 8 of the Investment Company Act of 1940;
    (e)   ☐    An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
    (f)   ☐    An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
    (g)   ☐    A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
    (h)   ☐    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)   ☐    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940;
    (j)   ☐    A non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J);
    (k)   ☐    Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution:

    If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:


    Item 4.

    Ownership

     

      (a)

    Amount beneficially owned:

    5,859,375

     

      (b)

    Percent of class: 8.9%(1)

     

      (c)

    Number of shares as to which the person has:

     

      (i)

    Sole power to vote or to direct the vote:

    5,859,375

     

      (ii)

    Shared power to vote or to direct the vote:

    0

     

      (iii)

    Sole power to dispose or to direct the disposition of:

    5,859,375

     

      (iv)

    Shared power to dispose or to direct the disposition of:

    0

     

    Item 5.

    Ownership of Five Percent or Less of a Class

    Not applicable.

     

    Item 6.

    Ownership of More than Five Percent on Behalf of Another Person

    Not applicable.

     

    Item 7.

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company

    Not applicable.

     

    Item 8.

    Identification and Classification of Members of the Group

    Not applicable.

     

    Item 9.

    Notice of Dissolution of Group

    Not applicable.

     

    Item 10.

    Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: March 24, 2023     MODERNATX, INC.
        By:  

    /s/ Brian Sandstrom

        Name:   Brian Sandstrom
        Title:   Vice President, Associate General Counsel, Securities
    Get the next $GBIO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GBIO

    DatePrice TargetRatingAnalyst
    10/19/2023Outperform → Market Perform
    TD Cowen
    11/8/2022$9.00Buy
    Canaccord Genuity
    12/15/2021$40.00 → $10.00Market Outperform
    JMP Securities
    12/15/2021$50.00 → $27.00Buy
    Needham
    12/14/2021Outperform → Mkt Perform
    William Blair
    More analyst ratings

    $GBIO
    Leadership Updates

    Live Leadership Updates

    See more
    • Tubulis Strengthens Executive Leadership with Appointment of Matthew Norkunas as Chief Financial Officer and President of Tubulis Inc.

      Tubulis today announced the appointment of Matthew Norkunas, MD, MBA, as Chief Financial Officer (CFO) and President of Tubulis Inc., further strengthening its management team at a pivotal stage of growth. Dr. Norkunas' proven track record of achieving financial and corporate goals for rapidly evolving biotechs will be instrumental in advancing Tubulis' strategic objectives. His unique background as a physician-turned-business executive will support the company's position as a leader and innovator in ADC drug development. Based in Tubulis' U.S. Cambridge office, Dr. Norkunas' appointment also expands the company's U.S. presence. "Tubulis has built a strong financial position to advance it

      2/6/25 5:00:00 AM ET
      $GBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Generation Bio Reports Business Highlights and First Quarter 2023 Financial Results

      Company entered into strategic collaboration with Moderna to use Generation Bio's proprietary non-viral genetic medicine delivery system for two liver disease programs and to co-develop novel targeting for immune cells Factor VIII expression data in non-human primates for wholly-owned hemophilia A program expected in 2023 First quarter 2023 cash balance of $288.6 million expected to fund operations into 2025; additional $47.5 million from Moderna collaboration received in second quarter 2023 CAMBRIDGE, Mass., May 10, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (NASDAQ:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent disea

      5/10/23 4:15:00 PM ET
      $GBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Generation Bio Appoints Yalonda Howze, J.D. as Chief Legal Officer

      CAMBRIDGE, Mass., April 05, 2023 (GLOBE NEWSWIRE) -- Generation Bio Co. (NASDAQ:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Yalonda Howze, J.D. has been appointed chief legal officer and secretary. "We are delighted to welcome Yalonda to the Generation Bio leadership team and look forward to drawing on her extensive legal expertise as we continue to execute on our vision of reaching the full potential of genetic medicine," said Geoff McDonough, M.D., president and chief executive officer of Generation Bio. "Generation Bio is pursuing an ambitious goal to develop lifelong, titratable gain of function DNA th

      4/5/23 7:30:00 AM ET
      $GBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GBIO
    SEC Filings

    See more
    • SEC Form S-8 filed by Generation Bio Co.

      S-8 - Generation Bio Co. (0001733294) (Filer)

      5/7/25 4:21:11 PM ET
      $GBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Generation Bio Co.

      10-Q - Generation Bio Co. (0001733294) (Filer)

      5/7/25 4:15:25 PM ET
      $GBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Generation Bio Co. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Generation Bio Co. (0001733294) (Filer)

      5/7/25 4:10:12 PM ET
      $GBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GBIO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CHIEF SCIENTIFIC OFFICER Samayoa Phillip converted options into 1,147 shares and covered exercise/tax liability with 337 shares, increasing direct ownership by 0.63% to 128,519 units (SEC Form 4)

      4 - Generation Bio Co. (0001733294) (Issuer)

      4/17/25 4:05:20 PM ET
      $GBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PRESIDENT AND CEO Mcdonough Geoff covered exercise/tax liability with 1,548 shares and converted options into 5,274 shares, increasing direct ownership by 0.28% to 1,349,664 units (SEC Form 4)

      4 - Generation Bio Co. (0001733294) (Issuer)

      4/17/25 4:05:18 PM ET
      $GBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CHIEF OPERATING OFFICER Paone Antoinette converted options into 1,592 shares and covered exercise/tax liability with 468 shares, increasing direct ownership by 5% to 23,082 units (SEC Form 4)

      4 - Generation Bio Co. (0001733294) (Issuer)

      4/17/25 4:05:13 PM ET
      $GBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GBIO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Generation Bio Co.

      SC 13G/A - Generation Bio Co. (0001733294) (Subject)

      12/9/24 6:18:02 PM ET
      $GBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Generation Bio Co.

      SC 13G/A - Generation Bio Co. (0001733294) (Subject)

      11/14/24 1:22:38 PM ET
      $GBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Generation Bio Co. (Amendment)

      SC 13G/A - Generation Bio Co. (0001733294) (Subject)

      2/14/24 10:03:03 AM ET
      $GBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GBIO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $GBIO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $GBIO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Director Quinn Anthony G. bought $203,209 worth of shares (210,791 units at $0.96), increasing direct ownership by 238% to 299,286 units (SEC Form 4)

      4 - Generation Bio Co. (0001733294) (Issuer)

      1/14/25 4:05:17 PM ET
      $GBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Appelhans Dannielle bought $14,339 worth of shares (8,000 units at $1.79), increasing direct ownership by 5% to 12,637 units (SEC Form 4)

      4 - Generation Bio Co. (0001733294) (Issuer)

      12/11/23 4:30:19 PM ET
      $GBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Appelhans Dannielle bought $18,000 worth of shares (12,000 units at $1.50) (SEC Form 4)

      4 - Generation Bio Co. (0001733294) (Issuer)

      12/6/23 4:30:13 PM ET
      $GBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Generation Bio downgraded by TD Cowen

      TD Cowen downgraded Generation Bio from Outperform to Market Perform

      10/19/23 7:43:32 AM ET
      $GBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Canaccord Genuity initiated coverage on Generation Bio with a new price target

      Canaccord Genuity initiated coverage of Generation Bio with a rating of Buy and set a new price target of $9.00

      11/8/22 6:17:49 AM ET
      $GBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • JMP Securities reiterated coverage on Generation Bio with a new price target

      JMP Securities reiterated coverage of Generation Bio with a rating of Market Outperform and set a new price target of $10.00 from $40.00 previously

      12/15/21 7:17:06 AM ET
      $GBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Generation Bio Reports Recent Business Highlights and First Quarter 2025 Financial Results

      -  Company continues to advance its strategy to develop first-in-class treatments for T cell-driven autoimmune diseases using its cell-targeted lipid nanoparticle (ctLNP) technology to deliver siRNA -  Lead target and portfolio strategy to be announced mid-2025 -  Cash balance of $157.6 million expected to fund operations into 2H 2027 CAMBRIDGE, MASS., May 07, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (NASDAQ:GBIO), a biotechnology company working to change what's possible for people living with T cell-driven autoimmune diseases, reported business highlights and first quarter 2025 financial results."Our selective, redosable cell-targeted lipid nanoparticle (ctLNP) delivery syste

      5/7/25 4:05:00 PM ET
      $GBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Generation Bio to Present at the Needham 24th Annual Virtual Healthcare Conference

      CAMBRIDGE, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (NASDAQ:GBIO), a biotechnology company working to change what's possible for people living with T cell-driven autoimmune diseases, announced that Geoff McDonough, M.D., president and chief executive officer, will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Wednesday, April 9th at 12:45 p.m. ET. A live webcast of the presentation will be available on the investor section of the company's website at investors.generationbio.com. A replay will be available there for 30 days following the event.   About Generation Bio Generation Bio is a biotechnology company working to chan

      4/2/25 6:59:00 AM ET
      $GBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Generation Bio Reports Business Highlights and Fourth Quarter and Full Year 2024 Financial Results

      -  Company is applying its T cell-selective lipid nanoparticle to develop siRNA therapeutics for T cell-driven autoimmune diseases -  Lead target and indication to be announced MY 2025 -  Cash balance of $185.2 million expected to fund operations into 2H 2027 CAMBRIDGE, MASS., March 13, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (NASDAQ:GBIO), a biotechnology company working to change what's possible for people living with T cell-driven autoimmune diseases, reported business highlights and fourth quarter and full year 2024 financial results. "Our T cell-selective lipid nanoparticle (LNP) is designed to overcome a

      3/13/25 4:05:00 PM ET
      $GBIO
      Biotechnology: Pharmaceutical Preparations
      Health Care